Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMERA trial in newly diagnosed rheumatoid arthritis
2024-511530-12-01Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate, filgotinib, golimumab, adalimumab, etanercept and 7 more in rheumatoid arthritis (RA) (2 arms), sponsored by Erasmus MC. Primary endpoints: Proportion of patients using a biologic or targeted synthetic DMARD after 10 months, Disease activity score over time and 1 more. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-511530-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511530-12-01.